D-α-Tocopherol Succinate
Based on 3 publication(s) in Google Scholar
D-α-Tocopherol Succinate (Vitamin E succinate) is an antioxidant tocopherol and a salt form of vitamin E. D-α-Tocopherol Succinate inhibits Cisplatin (HY-17394)-induced cytotoxicity. D-α-Tocopherol Succinate can be used for the research of cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98.0%
- CAS No.: 4345-03-3
- Formule: C33H54O5
- Masse moléculaire:530.78
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-B0166
L-Ascorbic acidAntioxidant -
HY-N0683
α-Vitamin EAntioxidant -
HY-B1278B
(±)-α-Tocopherol acetateVitamin E Acetate -
HY-W020044
DL-alpha-TocopherolVitamin E -
HY-B0143
NiacinB3 vitamin -
HY-B0430A
D-Pantothenic acid sodiumEndogenous Metabolite -
HY-N0683R
α-Vitamin E (Standard)Antioxidant -
HY-15398
Vitamin D3Vitamin -
HY-B1278BR
(±)-α-Tocopherol acetate (Standard)Vitamin E Acetate -
HY-W020044R
DL-alpha-Tocopherol (Standard)Vitamin E -
HY-131553R
D-α-Tocopherol Succinate (Standard)Tocopherol -
HY-B0166G
L-Ascorbic acid (GMP)Antioxidant
Publications Citing Use of MedChemExpress (MCE) D-α-Tocopherol Succinate
More
Activité biologique
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 4T1 | IC50 |
10 μM
Compound: 1, VES
|
Inhibition of mouse 4T1 cells adhesion to gelatinous matrix protein-coated surface after 60 mins by ELISA
Inhibition of mouse 4T1 cells adhesion to gelatinous matrix protein-coated surface after 60 mins by ELISA
|
[PMID: 19708661] |
| HCT-116 | IC50 |
52.3 μM
Compound: alpha-TOS
|
Cytotoxicity against Homo sapiens (human) HCT116 cells after 48 hr by SRB assay
Cytotoxicity against Homo sapiens (human) HCT116 cells after 48 hr by SRB assay
|
10.1007/s00044-011-9801-3 |
| HepG2 | IC50 |
245 μM
Compound: alpha-TOS
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 27344490] |
| HepG2 | IC50 |
55 μM
Compound: alpha-TOS
|
Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by SRB assay
Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by SRB assay
|
10.1007/s00044-011-9801-3 |
| MCF7 | IC50 |
>368 μM
Compound: alpha-TO-succinate
|
Compound was tested for antiproliferative activity against human breast cancer cell line MCF-7 in MTT assay
Compound was tested for antiproliferative activity against human breast cancer cell line MCF-7 in MTT assay
|
[PMID: 9873556] |
| MCF7 | IC50 |
57 μM
Compound: alpha-TOS
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 27344490] |
| MT4 | IC50 |
66 μM
Compound: alpha-TOS
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 27344490] |
| RPMI-8226 | IC50 |
63 μM
Compound: alpha-TOS
|
Cytotoxicity against human RPMI8226 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human RPMI8226 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 27344490] |
| U-937 | IC50 |
113 μM
Compound: alpha-TOS
|
Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 27344490] |
In Vitro
D-α-Tocopherol Succinate (1-20 μM; 24 hours) shows cytotoxicity to HEI-OC1 cells[1]. D-α-Tocopherol Succinate (10 μM; 48 hours) protects HEI-OC1 cells against cisplatin-induced ototoxicity and inhibits caspase-3 activity[1]. D-α-Tocopherol Succinate (0-50 μM; 18 hours) shows cytotoxicity to TC-1 tumor cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HEI-OC1 cell line
-
Concentration:1-20 μM
-
Incubation Time:24 hours
-
Result:Significantly induced cytotoxicity at a concentration of 20 μM and showed a higher cytotoxicity potency compared with 10 μM.
-
Cell Line:HEI-OC1 cell line
-
Concentration:10 μM
-
Incubation Time:48 hours
-
Result:Increased cisplatin-induced cell population. Inhibited cisplatin-induced necrotic, ROS production and late apoptosis. Decreased cleaved PARP and inhibited the expression of caspase-3 which related to cisplatin-induced apoptosis.
-
Cell Line:TC-1 tumor cells
-
Concentration:0, 25 and 50 μM
-
Incubation Time:18 hours
-
Result:Dose-dependently showed cytotoxic and induced a higher percentage of necrotic TC-1 cells as opposed to apoptotic cells.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Six- to eight-week-old female C57BL/6 mice with TC-1 tumor cells[2]
-
Dosage:1 and 2 mg/kg
-
Administration:Intraperitoneal injection; 1 and 2 mg/kg three times at 2 day intervals; from TC-1 tumor cells injection for 10 days to 14 days
-
Result:Dreased the tumor volume, especially with a dose of 2 mg/kg.
Chemical Information
-
CAS No. 4345-03-3
-
Appearance Solid
-
Masse moléculaire 530.78
-
Formule C33H54O5
-
Color White to off-white
-
SMILES
CC1=C2C(CC[C@](C)(O2)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C(OC(CCC(O)=O)=O)=C1C)C
-
Synonyms
Vitamin E succinate
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Donafenib and GSK-J4 Synergistically Induce Ferroptosis in Liver Cancer by Upregulating HMOX1 Expression. [Abstract]2023 Aug;10(22):e2206798. PMID: 37330650 -
Adv Healthc Mater
Cascade-Responsive Nanoprodrug Disrupts Immune-Fibroblast Communications for Potentiated Cancer Mechanoimmunotherapy. [Abstract]2025 Apr;14(11):e2500176. PMID: 40079115 -
Hum Reprod
Single-cell RNA sequencing reveals transcriptomic landscape and potential targets for human testicular ageing. [Abstract]2024 Oct 1;39(10):2189-2209. PMID: 39241251
Solvant et solubilité
In Vitro:
DMSO : 100 mg/mL (188.40 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (3.92 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Pureté et documentation
-
Fiche technique (274 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Kim SK, et al. The effects of the antioxidant α-tocopherol succinate on cisplatin-induced ototoxicity in HEI-OC1 auditory cells. Int J Pediatr Otorhinolaryngol. 2016 Jul;86:9-14. [Content Brief]
[2]. Kang TH, et al. Treatment of tumors with vitamin E suppresses myeloid derived suppressor cells and enhances CD8+ T cell-mediated antitumor effects. PLoS One. 2014 Jul 29;9(7):e103562. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8840 mL | 9.4201 mL | 18.8402 mL | 47.1005 mL |
| 5 mM | 0.3768 mL | 1.8840 mL | 3.7680 mL | 9.4201 mL | |
| 10 mM | 0.1884 mL | 0.9420 mL | 1.8840 mL | 4.7100 mL | |
| 15 mM | 0.1256 mL | 0.6280 mL | 1.2560 mL | 3.1400 mL | |
| 20 mM | 0.0942 mL | 0.4710 mL | 0.9420 mL | 2.3550 mL | |
| 25 mM | 0.0754 mL | 0.3768 mL | 0.7536 mL | 1.8840 mL | |
| 30 mM | 0.0628 mL | 0.3140 mL | 0.6280 mL | 1.5700 mL | |
| 40 mM | 0.0471 mL | 0.2355 mL | 0.4710 mL | 1.1775 mL | |
| 50 mM | 0.0377 mL | 0.1884 mL | 0.3768 mL | 0.9420 mL | |
| 60 mM | 0.0314 mL | 0.1570 mL | 0.3140 mL | 0.7850 mL | |
| 80 mM | 0.0236 mL | 0.1178 mL | 0.2355 mL | 0.5888 mL | |
| 100 mM | 0.0188 mL | 0.0942 mL | 0.1884 mL | 0.4710 mL |
D-α-Tocopherol Succinate Related Classifications
HY-131553 Related Classifications
Powered by Bioz